Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 311Neoplasm Metastasis 38Neoplasms 22Advanced Breast Cancer 19Ovarian Neoplasms 18Carcinoma, Non-Small-Cell Lung 14Endometrial Neoplasms 11Prostatic Neoplasms 10Hereditary Sensory and Autonomic Neuropathies 10Triple Negative Breast Neoplasms 8Colorectal Neoplasms 6Breast Cancer Metastatic 6Uterine Cervical Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Recurrence 5Carcinoma, Ovarian Epithelial 5Neoplasms by Site 4Multiple Endocrine Neoplasia Type 1 4Breast Diseases 4Stomach Neoplasms 3Small Cell Lung Carcinoma 3Lung Neoplasms 3Head and Neck Neoplasms 3Fallopian Tube Neoplasms 3Carcinoma, Lobular 3Uterine Neoplasms 2Pancreatic Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Lymphoma 2

Interventions

palbociclib 2Letrozole 2Fulvestrant 2pyrotinib 1Trastuzumab 1Diet, Ketogenic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Estrogen Receptor-positive Breast Cancer × Fulvestrant × Clear all
NCT03633331 2026-04-29

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Completed
93 enrolled 16 charts
Breast

Estrogen Receptor-positive Breast Cancer

NCT05076695 2021-10-13

NeoTPPF

Fudan University

Phase 2 Unknown
37 enrolled
Breast

Estrogen Receptor-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡